{Reference Type}: Journal Article
{Title}: Clinical Pipelines for Alzheimer's Disease Psychosis and Agitation.
{Author}: Oguma T;Jino K;
{Journal}: Chem Pharm Bull (Tokyo)
{Volume}: 72
{Issue}: 7
{Year}: 2024
{Factor}: 1.903
{DOI}: 10.1248/cpb.c23-00416
{Abstract}: Agitation and psychosis are key behavioral and psychological symptoms of Alzheimer's disease (AD). For family and caregivers of patients, such symptoms are critical factors of distress and increased burden, but medication to treat them is limited. In most cases, drugs for other neuropsychiatric diseases have been used to manage these symptoms in an off-label manner. Due to the complex pathological background of AD and limited clinical data, obtaining proof of concept for the treatment of these symptoms is challenging. However, in 2023, the U.S. Food and Drug Administration approved brexpiprazole as the first and only drug to treat agitation in AD. Several other compounds have been evaluated in clinical situations. This review highlights recent pipelines being developed for agitation and psychosis for patients living with AD.